NEW YORK, Jan. 27, 2021 – Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer....
treatment News
Seattle, Washinton – Of the 38 million Americans who have diabetes at least 90% have Type 2, according to the Centers for Disease Control and Prevention. Type 2 diabetes occurs over time and is characterized by a loss of the cells in the pancreas that make the hormone insulin, which...
Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics’ small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced Soft Tissue Sarcoma (STS). An Objective Response Rate (ORR) of 80% was achieved, based on the Best Observed Response (BOR) at any time during the study, indicating...
Miami, Florida – The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent. Over the last decade, options have evolved from double, to triple to quadruple combination...
BILLERICA, Mass. — Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s...
London, UK – Researchers have developed a revolutionary biosensor using terahertz (THz) waves that can detect skin cancer with exceptional sensitivity, potentially paving the way for earlier and easier diagnoses. Published in the IEEE Transactions on Biomedical Engineering, the study presents a significant advancement in early cancer detection, thanks to...
CHICAGO, Illinois — Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial of QTX-2101, an investigational oral arsenic trioxide capsule. The trial will evaluate the efficacy, safety, and pharmacokinetics of QTX-2101, as a potential new treatment for acute promyelocytic leukemia...
SOUTH SAN FRANCISCO, Calif. – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB)...
SOUTH SAN FRANCISCO, Calif. –– Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of...
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va. — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases,...